Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CRISPR THERAPEUTICS AG

(CRSP)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
52.78 USD   +4.58%
01/19JMP Securities Adjusts Price Target on CRISPR Therapeutics to $70 From $100, Maintains Market Outperform Rating
MT
01/12CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology Conference
AQ
01/11CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Number of employees : 473 people.
Sales per Business
20202021Delta
Collaboration0.5475.5%913.0899.8% +168054.88%
Grant0.1824.5%1.880.2% +969.32%
USD in Million
Sales per region
20202021Delta
Switzerland and United States0.72100%914.96100% +127154.94%
USD in Million
Managers
Name Title Age Since
Samarth Kulkarni Chief Executive Officer & Executive Director 43 2018
Rodger Novak Chairman & President 54 2017
Brendan Smith Chief Financial Officer 46 2021
Jonathan Terrett Head-Research - -
Stephen Kennedy Head-Technical Operations 65 2019
Phuong Khanh Morrow Chief Medical Officer - 2022
Susan Kim Investor Relations Contact - -
James R. Kasinger Secretary & General Counsel 50 2017
Shelby Walker Head-Intellectual Property - -
Alex Harding, Dr. Head-Business Development & Senior Vice President - 2023
Members of the board
Name Title Age Since
Rodger Novak Chairman & President 54 2017
Simeon J. George, Dr. Independent Non-Executive Director 45 2015
Ali Behbahani, Dr. Independent Non-Executive Director 45 2015
Bradley Bolzon Independent Director 62 2014
Katherine A. High, Dr. Independent Director 70 2019
John Greene Independent Director 56 2019
Douglas A. Treco, Dr. Independent Director 64 2020
Harold Edward Fleming Independent Director 59 2021
Samarth Kulkarni Chief Executive Officer & Executive Director 43 2018
Maria Fardis Director 54 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,474,455 77,228,142 98.4% 180,316 0.2% 98.4%
Shareholders
NameEquities%
ARK Investment Management LLC 7,829,932 10.0%
Capital Research & Management Co. (International Investors) 5,342,418 6.82%
Nikko Asset Management Americas, Inc. 4,262,736 5.44%
T. Rowe Price Investment Management, Inc. 2,241,445 2.86%
NEA Management Co. LLC 1,590,002 2.03%
SSgA Funds Management, Inc. 1,568,384 2.00%
The Vanguard Group, Inc. 1,350,107 1.72%
Perceptive Advisors LLC 1,341,308 1.71%
Fidelity Management & Research Co. LLC 1,317,981 1.68%
Loomis, Sayles & Co. LP 1,245,199 1.59%
Company contact information
CRISPR Therapeutics AG
Baarerstrasse 14
Zug 6300

Phone : +41.41.561.32.77
Web : http://www.crisprtx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of CRISPR Therapeutics AG